Neuromonics Announces Publication of Private Practice
Tinnitus Treatment Study
Editor: You may be familiar with Neuromonics, a company that offers
treatment for tinnitus. A recently completed study commissioned by them
seems to support the conclusion that the Neuromonics treatment is
effective for treating tinnitus. Here's their press release.
Neuromonics Inc has announced publication of the largest
private-practice study evaluating the Neuromonics Tinnitus Treatment,
which comprehensively targets the condition's neurological processes.
Published in the November issue of Annals of Otology, Rhinology &
Laryngology, the 470-patient study demonstrates that 92% of the patient
cohort who met suitability criteria significantly improved following the
Neuromonics Tinnitus Treatment.
This is the first study that evaluated the Neuromonics Tinnitus
Treatment's efficacy for the entire tinnitus population; the study did not
just include the most suitable patients, but also more difficult-to-treat
sufferers with complicating clinical factors. The research showed that the
treatment also improved symptoms for those patients with complications,
including those who also presented with decreased loudness tolerance (hyperacusis)
or severe hearing loss. The results provide instructive guidance to health
care professionals, by demonstrating how defined criteria relating to
treatment suitability impacts treatment outcomes.
"This data further validates the Neuromonics Tinnitus Treatment's
effectiveness for difficult-to-treat patients with limited therapeutic
options," said Peter Hanley, PhD, study co-author. "This is the first
study to reflect the broad diversity of patients seen in a 'real world'
private practice clinic setting, and demonstrates that the Neuromonics
Tinnitus Treatment leads to significant improvements for a broad cross
section of patients with tinnitus. By comprehensively addressing tinnitus'
underlying neurological processes, Neuromonics is uniquely positioned to
help the millions of patients seeking quality-of-life improvements."
Traditional treatment options for tinnitus sufferers have offered
limited long-term benefit. Notably, 49% of the patients in this study had
previously tried other common treatments, with limited success. And
importantly, unlike traditional therapies, the Neuromonics Tinnitus
Treatment led to rapid changes in tinnitus disturbance in this study. The
data shows 78% of the overall benefit reported by patients through the
course of treatment occurred during the first 10 weeks of treatment.
While the study's 470 patients all had tinnitus, a condition commonly
characterized by ringing in the ears, they differed in their level of
symptom severity and clinical profile; for example, the existence of
associated clinical complications. All patients were fitted with the
Neuromonics device and provided with treatment in a network of
private-practice clinics. The study compared treatment outcomes across
three cohorts, to which patients were assigned based on pre-defined
criteria, including their psychological state and level of hearing loss.
The Neuromonics Tinnitus Treatment delivers a prescribed acoustic
neural stimulus, customized for each patient's individual audiological
profile, and incorporating specially processed, relaxing music. The
stimulus is designed to provide relief and relaxation in the initial phase
of treatment, and then progressively over a period of several months, to
facilitate desensitization to the tinnitus. In this way, the therapy can
help the brain filter out the tinnitus perception, so that it no longer
intrudes on the patient's conscious attention, and no longer has a
disturbing impact on quality of life. By targeting the condition's
underlying neurological basis, Neuromonics may offer enhanced
effectiveness for patients compared to alternatives.
About the Neuromonics Tinnitus Treatment
Neuromonics' noninvasive, FDA-cleared device is customized to the
patient's unique hearing and tinnitus profile. It delivers a customized
neural stimulus that targets the brain's auditory pathways and is believed
to aid in neuroplasticity, or the process of neuronal change. This process
appears to be involved in allowing the brain to filter out the disturbing
tinnitus perception. This stimulus incorporates spectrally modified,
customized music, which engages the brain's emotional response center, the
limbic system, and thereby reduces tinnitus-related disturbance. Research
published in the April 2007 issue of Ear & Hearing demonstrates the
Neuromonics Tinnitus Treatment yields clinically significant reduction in
tinnitus disturbance in more than 90% of suitable patients in a formal
clinical trial setting. The Neuromonics Tinnitus Treatment is the most
comprehensive, long-term therapy that targets the neurological processes
of tinnitus; specifically, its audiological, attention-based, and
Clinically administered and monitored, the Neuromonics Tinnitus
Treatment is proven to yield significant long-term reduction of tinnitus
disturbance. The therapy is delivered via a compact, lightweight and
uniquely designed medical device. Treatment typically occurs over an
approximately six-month period, with daily use recommended for two or more
hours per day, especially when the tinnitus is most disturbing. The
treatment can take place during regular activities such as reading,
relaxing or computer work.
With global headquarters based in Bethlehem, Pa., Neuromonics is the
manufacturer and distributor of the only FDA-cleared, patented and
clinically proven medical device designed for long-term significant relief
of tinnitus. With research and development beginning in the early 1990s,
the Neuromonics Tinnitus Treatment has treated thousands of tinnitus
sufferers worldwide. Neuromonics' goal is to help tinnitus sufferers
improve their quality of life and overcome the daily-life challenges
associated with tinnitus. For more information, go to www.neuromonics.com.